Global Blood Therapeutics Appoints Ted W. Love, M.D., to the Company’s Board of Directors

  Global Blood Therapeutics Appoints Ted W. Love, M.D., to the Company’s Board
  of Directors

Business Wire

SAN FRANCISCO -- September 19, 2013

Global Blood Therapeutics, a product-focused company developing novel,
orally-available therapeutics for chronic blood diseases, today announced the
appointment of Ted W. Love, M.D., to the company’s board of directors. Dr.
Love most recently served as executive vice president, research and
development and technical operations at Onyx Pharmaceuticals.

“Ted is a seasoned industry leader with extensive drug development experience
and an impressive track record of moving drug candidates through the clinic to
approval,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer of
Global Blood Therapeutics and partner at Third Rock Ventures. “We are pleased
to welcome him to the Global Blood Therapeutics team as we continue to advance
our pipeline of preclinical programs focused on blood diseases, including
sickle cell disease. We fully expect Ted to have significant impact in helping
us fulfill our vision of changing the treatment paradigm for chronic blood
diseases.”

Dr. Love has more than 20 years of broad leadership and management experience
in the pharmaceutical industry. In his most recent position at Onyx, he played
an instrumental role in initiating and completing several of Onyx’s first
Phase 3 clinical trials. Prior to Onyx, Dr. Love served as president, chief
executive officer and chairman of Nuvelo, Inc., where he led growth of the
company to a market capitalization of $1 billion, and previously served as
senior vice president, development at Theravance, Inc. Earlier in his career,
Dr. Love held roles of increasing responsibility in medical affairs and
product development at Genentech. As vice president, product development, Dr.
Love oversaw the development strategy and execution leading to approvals of
Rituxan, Herceptin, Xolair, TNKase, Raptiva and Avastin. Dr. Love has served
as a consultant in medicine at Massachusetts’s General Hospital in the
department of cardiology. Dr. Love currently sits on the board of directors of
Santarus, Amicus Therapeutics, Oncothryeon, Avillion and KaloBios. He holds a
B.A. in molecular biology from Haverford College and an M.D. from Yale Medical
School.

“I have a longstanding interest in trying to solve sickle cell disease and
other chronic blood diseases that are inadequately served,” said Dr. Love.
“The current standard of care for sickle cell disease focuses on treating
acute symptoms, despite the chronic, underlying disease process that causes
progressive damage to the vital organs. What I find most compelling about
Global Blood Therapeutics’ approach is its emphasis on addressing fundamental
mechanisms of disease, not just the symptoms, and I look forward to helping
advance these potentially breakthrough therapeutics.”

About Global Blood Therapeutics

Global Blood Therapeutics is a product-focused company developing novel,
orally-available therapeutics for chronic blood diseases. The Company is
addressing severe, non-malignant blood-based diseases for which there are
currently no effective cures and only limited therapeutic options. Global
Blood Therapeutics is focused on the critical need for therapeutics that
address the underlying causes of blood diseases, not just the symptoms. The
Company’s extensive drug discovery capabilities — combining world-class
medicinal chemistry with deep expertise in blood biology — are driving its
product pipeline of mechanism-based therapeutics, including programs in sickle
cell disease and hereditary angioedema. Global Blood Therapeutics is a private
company launched in 2012 by Third Rock Ventures with an experienced leadership
team and renowned scientific founders. For more information, please visit
www.globalbloodtx.com

Contact:

Pure Communications
Alicia Gronneberg, 910-239-5036
Alicia@purecommunicationsinc.com